Sorafenib Therapy in Patients with Advanced Hepatocellular Carcinoma in Advanced Liver Cirrhosis

Digestion ◽  
2011 ◽  
Vol 83 (4) ◽  
pp. 275-282 ◽  
Author(s):  
Kerstin Schütte ◽  
Lars Zimmermann ◽  
Jan Bornschein ◽  
Antal Csepregi ◽  
Ricarda Rühl ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Therapy ◽  
Advanced Liver Cirrhosis

scholarly journals Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series

2021 ◽  
pp. 224-231
Author(s):  
Richard T. Lee ◽  
Peiying Yang ◽  
Asrar Alahmadi ◽  
Jennifer McQuade ◽  
Eric Yuan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Time ◽  
Injection Site Reaction ◽  
Case Series ◽  
Advanced Hepatocellular Carcinoma ◽  
Site Reaction ◽  
Advanced Hcc ◽  
Mistletoe Extract ◽  
Sorafenib Therapy ◽  
Mistletoe Extracts

Background: Hepatocellular carcinoma (HCC) is the fourth leading cause of death from cancer worldwide, and for advanced HCC the prognosis is poor. Preliminary studies indicate mistletoe extracts may have anticancer activity for HCC. Methods: A prospective observational case series of advanced HCC patients that chose to take a mistletoe extract called viscum fraxini-2 (VF-2) alone for treatment. Time on treatment, imaging, and laboratory values were collected for descriptive analyses. Results: A total of 12 patients with advanced HCC enrolled onto the protocol, and 10 patients had data available for evaluation. The majority were male (10/12) with a median age of 64 (SD 11). Most patients had received sorafenib therapy (9/12) and had varying Child-Pugh classes (A-4, B-6, C-2). Treatment with VF-2 ranged from 1 to 36 weeks with a mean of 12.3 weeks (SD 12). Six patients received 8 weeks of treatment, and 3 patients received 12 or more weeks of treatment. For patients that received at least 4 weeks of treatment, the average AFP value stabilized during the first 4 weeks of treatment. Two patients experienced an AFP decrease of >30%, approximately 37 and 40% decreases at the nadir. One patient had stable disease of 9 months. Major side effects were fever, fatigue, rash, and local injection site reaction of swelling, redness, and tenderness. Conclusion: This case series of advanced HCC indicates that mistletoe extract VF-2 may have potential biological activity against HCC for selected patients. Research is needed to identify the active compound and predictive markers of response.

The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis

Cancer ◽  
2012 ◽  
Vol 118 (21) ◽  
pp. 5293-5301 ◽  
Author(s):  
Joanne Chiu ◽  
Yuen Fong Tang ◽  
Tzy-Jyun Yao ◽  
Ashley Wong ◽  
Hilda Wong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Single Agent ◽  
Advanced Hepatocellular Carcinoma

scholarly journals Value of α‑fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma

2018 ◽  
Author(s):  
Ana Plano S�nchez ◽  
Luc�a Velasco Roces ◽  
Isabel Zapico Garc�a ◽  
Eva L�zaro L�pez ◽  
Miguel Calleja Hernandez ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Response ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Therapy ◽  
Early Biomarker

Outcomes of sorafenib therapy in advanced hepatocellular carcinoma in a single center in Ethiopia

2020 ◽  
Vol 32 (10) ◽  
pp. 1407-1408
Author(s):  
Elizabeth S. Aby ◽  
Amir Sultan ◽  
Abate Bane ◽  
Zerihun Wondifraw ◽  
Jose D. Debes
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Single Center ◽  
Sorafenib Therapy

Safety of Sorafenib Therapy in Elderly Adults with Advanced Hepatocellular Carcinoma

2014 ◽  
Vol 62 (11) ◽  
pp. 2204-2205 ◽  
Author(s):  
Edoardo Francini ◽  
Silvia Mazzaroppi ◽  
Anna I. Fiaschi ◽  
Roberto Petrioli ◽  
Letizia Laera ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Elderly Adults ◽  
Sorafenib Therapy

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

2009 ◽  
Vol 43 (5) ◽  
pp. 489-495 ◽  
Author(s):  
Marcus Alexander Wörns ◽  
Arndt Weinmann ◽  
Kerstin Pfingst ◽  
Carla Schulte-Sasse ◽  
Claudia-Martina Messow ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Advanced Hepatocellular Carcinoma ◽  
Safety And Efficacy

scholarly journals Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report

2017 ◽  
Vol 14 (4) ◽  
pp. 4853-4856 ◽  
Author(s):  
Jung Gil Park ◽  
Won Young Tak ◽  
Soo Young Park ◽  
Young Oh Kweon ◽  
Se Young Jang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Case Report ◽  
Complete Remission ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Therapy ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document